Published in Ann N Y Acad Sci on June 01, 2002
BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab (2008) 1.95
Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab (2010) 1.59
AP-2γ regulates oestrogen receptor-mediated long-range chromatin interaction and gene transcription. EMBO J (2011) 1.49
Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab (2008) 1.31
RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Res (2008) 1.30
Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist (2011) 1.27
Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta (2009) 1.18
Medullary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin North Am (2007) 1.14
ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer (2005) 1.12
Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer (2009) 1.08
The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? Oncotarget (2010) 0.98
Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability. Biophys J (2009) 0.89
Molecular pathogenesis of MEN2-associated tumors. Fam Cancer (2005) 0.88
Role of surgeons in clinical trials for thyroid cancer. World J Surg (2007) 0.87
The Hirschsprung's-multiple endocrine neoplasia connection. Clinics (Sao Paulo) (2012) 0.85
Mapping of a novel MEN-like syndrome locus to rat chromosome 4. Mamm Genome (2004) 0.84
Association between single-nucleotide polymorphisms of BRAF and papillary thyroid carcinoma in a Chinese population. Thyroid (2013) 0.83
Searching for non-RET molecular alterations in medullary thyroid carcinoma: expression analysis by mRNA differential display. World J Surg (2005) 0.83
siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. Nucleic Acids Res (2007) 0.80
NrCAM, a neuronal system cell-adhesion molecule, is induced in papillary thyroid carcinomas. Br J Cancer (2007) 0.79
Human thyroid tumours, the puzzling lessons from E7 and RET/PTC3 transgenic mice. Br J Cancer (2008) 0.76
New agents in the treatment for malignancies of the salivary and thyroid glands. Hematol Oncol Clin North Am (2008) 0.75
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab (2003) 4.93
Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med (2002) 4.69
MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer (2007) 3.53
Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med (2005) 3.35
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res (2002) 3.33
DNA damage, homology-directed repair, and DNA methylation. PLoS Genet (2007) 2.29
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res (2003) 2.26
Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett (2004) 2.17
Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res (2005) 2.10
Retracted The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest (2005) 2.09
Functional variants of the HMGA1 gene and type 2 diabetes mellitus. JAMA (2011) 2.00
Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene (2002) 1.99
Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. Int J Cardiol (2013) 1.99
RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab (2006) 1.98
HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell (2006) 1.96
New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab (2008) 1.76
Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice. Nat Med (2005) 1.64
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene (2004) 1.63
Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab (2009) 1.59
Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene (2005) 1.53
Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nat Clin Pract Endocrinol Metab (2006) 1.50
Increased BDNF promoter methylation in the Wernicke area of suicide subjects. Arch Gen Psychiatry (2010) 1.49
A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res (2007) 1.47
HMGA and cancer. Biochim Biophys Acta (2010) 1.45
BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res (2006) 1.43
The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Am J Pathol (2004) 1.43
Thyroid cancer and inflammation. Mol Cell Endocrinol (2009) 1.37
Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab (2004) 1.36
Haploinsufficiency of the Hmga1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice. Cancer Res (2006) 1.34
Retracted High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. J Clin Invest (2007) 1.34
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol (2006) 1.29
Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res (2008) 1.28
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr Relat Cancer (2010) 1.28
MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1alpha. J Clin Endocrinol Metab (2011) 1.28
Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization. Cell Cycle (2003) 1.25
Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein. Cancer Res (2009) 1.25
CBX7 is a tumor suppressor in mice and humans. J Clin Invest (2012) 1.24
HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression. Clin Cancer Res (2004) 1.23
Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. Eur J Cancer (2010) 1.21
Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol Cell Biol (2003) 1.20
Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. Carcinogenesis (2005) 1.18
Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. Am J Pathol (2005) 1.18
Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer Res (2007) 1.17
Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin Endocrinol Metab (2005) 1.17
Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas. Endocr Relat Cancer (2010) 1.16
HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. Cancer Res (2009) 1.16
Altered microRNA expression profile in human pituitary GH adenomas: down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1. J Clin Endocrinol Metab (2012) 1.15
The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. Eur J Cancer (2010) 1.15
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene (2004) 1.14
HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur J Cancer (2008) 1.14
Identification of a New Pathway for Tumor Progression: MicroRNA-181b Up-Regulation and CBX7 Down-Regulation by HMGA1 Protein. Genes Cancer (2010) 1.13
TACC3 mediates the association of MBD2 with histone acetyltransferases and relieves transcriptional repression of methylated promoters. Nucleic Acids Res (2006) 1.12
TAZ/WWTR1 is overexpressed in papillary thyroid carcinoma. Eur J Cancer (2010) 1.12
Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab (2002) 1.12
The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. Cancer Res (2009) 1.11
HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma. Histopathology (2012) 1.11
HMGA1 and HMGA2 protein expression in mouse spermatogenesis. Oncogene (2002) 1.11
Regulation of BRCA1 transcription by specific single-stranded DNA binding factors. Mol Cell Biol (2003) 1.10
Akt-dependent T198 phosphorylation of cyclin-dependent kinase inhibitor p27kip1 in breast cancer. Cell Cycle (2004) 1.10
UbcH10 is overexpressed in malignant breast carcinomas. Eur J Cancer (2007) 1.10
Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness. Clin Cancer Res (2005) 1.09
The rat tyrosine phosphatase eta increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue. Oncogene (2005) 1.08
Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. J Clin Endocrinol Metab (2012) 1.08
The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis. Oncogene (2004) 1.08
HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis (2003) 1.07
Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer. Cancer Res (2011) 1.07
Minireview: RET: normal and abnormal functions. Endocrinology (2004) 1.06
The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol (2002) 1.06
HIPK2 controls cytokinesis and prevents tetraploidization by phosphorylating histone H2B at the midbody. Mol Cell (2012) 1.05
The cAMP-HMGA1-RBP4 system: a novel biochemical pathway for modulating glucose homeostasis. BMC Biol (2009) 1.04
High-mobility group A1 proteins regulate p53-mediated transcription of Bcl-2 gene. Cancer Res (2010) 1.04
Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Res (2009) 1.03
miR-191 down-regulation plays a role in thyroid follicular tumors through CDK6 targeting. J Clin Endocrinol Metab (2011) 1.03
FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders. BMC Cancer (2007) 1.03
Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene (2002) 1.03
Loss of Hmga1 gene function affects embryonic stem cell lympho-hematopoietic differentiation. FASEB J (2003) 1.02
The High Mobility Group A proteins contribute to thyroid cell transformation by regulating miR-603 and miR-10b expression. Mol Oncol (2013) 1.02
Oncogenic alterations in papillary thyroid cancers of young patients. Thyroid (2011) 1.01
H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization. Oncogene (2004) 1.01
Restoration of receptor-type protein tyrosine phosphatase eta function inhibits human pancreatic carcinoma cell growth in vitro and in vivo. Carcinogenesis (2004) 1.00
HMGA1 silencing restores normal stem cell characteristics in colon cancer stem cells by increasing p53 levels. Oncotarget (2014) 1.00
Fra-1 promotes growth and survival in RAS-transformed thyroid cells by controlling cyclin A transcription. EMBO J (2007) 1.00
Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors. Oncogene (2005) 0.99
Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis. DNA Cell Biol (2006) 0.99
An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo. Cancer Res (2003) 0.99
The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. Cancer Res (2006) 0.98